CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands |
3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2018 |
Sep. 30, 2018 |
Jun. 30, 2018 |
Mar. 31, 2018 |
Dec. 31, 2017 |
Sep. 30, 2017 |
Jun. 30, 2017 |
Mar. 31, 2017 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
|
| Revenue: | |||||||||||
| Total revenue | $ 647,094,000 | $ 619,469,000 | $ 529,755,000 | ||||||||
| Cost of sales: | |||||||||||
| Total cost of sales | $ 138,597,000 | $ 128,569,000 | $ 126,731,000 | $ 118,496,000 | $ 120,539,000 | $ 112,951,000 | $ 118,090,000 | $ 110,540,000 | 512,393,000 | 462,120,000 | 365,470,000 |
| Gross margin | 22,011,000 | 35,458,000 | 39,231,000 | 38,001,000 | 39,059,000 | 38,586,000 | 37,652,000 | 42,052,000 | 134,701,000 | 157,349,000 | 164,285,000 |
| Operating expenses: | |||||||||||
| Sales and marketing | 8,104,000 | 8,989,000 | 10,877,000 | 9,654,000 | 10,565,000 | 9,332,000 | 10,029,000 | 11,012,000 | 37,624,000 | 40,938,000 | 30,941,000 |
| Product development | 7,033,000 | 7,477,000 | 9,872,000 | 8,358,000 | 8,689,000 | 11,328,000 | 7,942,000 | 7,649,000 | 32,740,000 | 35,608,000 | 37,718,000 |
| General and administrative | 134,663,000 | 148,221,000 | 115,195,000 | ||||||||
| Provision for legal settlements | 1,317,000 | 1,435,000 | 43,446,000 | ||||||||
| Amortization of intangible assets | 7,889,000 | 9,447,000 | 10,357,000 | 10,747,000 | 11,106,000 | 10,981,000 | 10,860,000 | 11,008,000 | 38,440,000 | 43,955,000 | 35,648,000 |
| Goodwill impairment | 0 | 0 | 0 | 0 | 89,000,000 | 0 | 0 | 78,000,000 | 0 | 167,000,000 | 64,000,000 |
| Total operating expenses | 59,436,000 | 57,024,000 | 60,764,000 | 67,560,000 | 158,852,000 | 71,080,000 | 63,760,000 | 143,465,000 | 244,784,000 | 437,157,000 | 326,948,000 |
| Loss from operations | (37,425,000) | (21,566,000) | (21,533,000) | (29,559,000) | (119,793,000) | (32,494,000) | (26,108,000) | (101,413,000) | (110,083,000) | (279,808,000) | (162,663,000) |
| Other income (expense), net: | |||||||||||
| Interest expense, net | (20,818,000) | (20,048,000) | (19,755,000) | (15,597,000) | (14,519,000) | (18,164,000) | (14,807,000) | (10,964,000) | (76,218,000) | (58,454,000) | (18,198,000) |
| Loss on extinguishment of debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (14,389,000) | 0 | (14,389,000) | 0 |
| Income (loss) from equity method investments including impairment losses | (49,921,000) | 2,022,000 | 428,000 | 1,161,000 | (16,334,000) | 1,770,000 | 601,000 | 1,539,000 | (46,310,000) | (12,424,000) | 3,829,000 |
| Change in fair value of derivatives | 384,000 | (196,000) | (655,000) | 564,000 | 839,000 | 196,000 | (445,000) | 2,920,000 | 97,000 | 3,510,000 | 25,515,000 |
| Other expense, net | (194,000) | (588,000) | (673,000) | 438,000 | (478,000) | (123,000) | 653,000 | (488,000) | (1,017,000) | (436,000) | (6,326,000) |
| Loss before income taxes | (107,974,000) | (40,376,000) | (42,188,000) | (42,993,000) | (150,285,000) | (48,815,000) | (40,106,000) | (122,795,000) | (233,531,000) | (362,001,000) | (157,843,000) |
| Income tax provision (benefit) | 1,203,000 | 2,852,000 | 3,722,000 | (4,709,000) | (15,880,000) | 4,153,000 | 4,024,000 | 2,816,000 | 3,068,000 | (4,887,000) | (44,911,000) |
| Net loss | $ (109,177,000) | $ (43,228,000) | $ (45,910,000) | $ (38,284,000) | $ (134,405,000) | $ (52,968,000) | $ (44,130,000) | $ (125,611,000) | $ (236,599,000) | $ (357,114,000) | $ (112,932,000) |
| Net loss per share: | |||||||||||
| Basic (in usd per share) | $ (1.19) | $ (0.47) | $ (0.50) | $ (0.42) | $ (1.51) | $ (0.59) | $ (0.52) | $ (1.47) | $ (2.59) | $ (4.07) | $ (1.39) |
| Diluted (in usd per share) | $ (1.19) | $ (0.47) | $ (0.50) | $ (0.42) | $ (1.51) | $ (0.59) | $ (0.52) | $ (1.47) | $ (2.59) | $ (4.07) | $ (1.39) |
| Weighted average shares outstanding: | |||||||||||
| Basic (in shares) | 91,848 | 91,408 | 91,057 | 90,792 | 89,222 | 89,194 | 85,496 | 85,440 | 91,325 | 87,733 | 81,269 |
| Diluted (in shares) | 91,848 | 91,408 | 91,057 | 90,792 | 89,222 | 89,194 | 85,496 | 85,440 | 91,325 | 87,733 | 81,269 |
| Licensing & Services | |||||||||||
| Revenue: | |||||||||||
| Total revenue | $ 606,227,000 | $ 581,920,000 | $ 496,535,000 | ||||||||
| Cost of sales: | |||||||||||
| Total cost of sales | 480,864,000 | 428,619,000 | 336,702,000 | ||||||||
| Equipment | |||||||||||
| Revenue: | |||||||||||
| Total revenue | 40,867,000 | 37,549,000 | 33,220,000 | ||||||||
| Cost of sales: | |||||||||||
| Total cost of sales | $ 31,529,000 | $ 33,501,000 | $ 28,768,000 | ||||||||
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of nonoperating interest income (expense). No definition available.
|
| X | ||||||||||
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|